Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype/a inhibit catalytic activity

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Fan, Yongfeng ^a   Geren, Isin N ^a,e   Dong, Jianbo ^a   Lou, Jianlong ^a   Wen, Weihua ^a   Conrad, Fraser ^a   Smith, Theresa J ^b   Smith, Leonard A ^c   Ho, Mengfei ^d   Pires Alves, Melissa ^d   Wilson, Brenda A ^d   Marks, James D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDES AND PROTEINS; PROTEIN SNAP25; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; ANTITOXIN; NEUROTOXIN;

ADULT; ANIMAL CELL; ANTIBODY ISOLATION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IC50; LIGHT CHAIN; MOUSE; MUTAGENESIS; NONHUMAN; PROTEIN CLEAVAGE; YEAST; ANIMAL; CHEMISTRY; EPITOPE MAPPING; IMMUNOLOGY; METABOLISM; PROTEIN TERTIARY STRUCTURE; SEROTYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTITOXINS; BOTULINUM TOXINS, TYPE A; CATALYSIS; EPITOPE MAPPING; FEMALE; HUMANS; MICE; NEUROTOXINS; PROTEIN STRUCTURE, TERTIARY; SEROGROUP; SINGLE-CHAIN ANTIBODIES;

EID: 84940837223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135306     Document Type: Article

References (59)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285: 1059-1070. PMID: 11209178
2. Marks JD (2004) Medical aspects of biologic toxins. Anesthesiol Clin North America 22: 509-532, vii. PMID: 15325716
3. Schechter R, Arnon SS (2000) Extreme potency of botulinum toxin. Lancet 355: 237-238.
4. Lacy DB, Stevens RC (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291: 1091-1104. PMID: 10518945
5. Barash JR, Arnon SS (2014) A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 209: 183-191. doi: 10.1093/infdis/jit449 PMID: 24106296
6. Dover N, Barash JR, Hill KK, Xie G, Arnon SS (2014) Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 209: 192-202. doi: 10.1093/infdis/jit450 PMID: 24106295
7. Kalb SR, Baudys J, Raphael BH, Dykes JK, Luquez C, Maslanka SE, et al. (2015) Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal Chem 87: 3911-3917. doi: 10.1021/ac504716v PMID: 25731972
8. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5: 898-902. PMID: 9783750
9. Dolly JO, Black J, Williams RS, Melling J (1984) Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307: 457-460. PMID: 6694738
10. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596. PMID: 16543415
11. Montecucco C, Rossetto O, Schiavo G (2004) Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol 12: 442-446. PMID: 15381192
12. Blaustein RO, Germann WJ, Finkelstein A, DasGupta BR (1987) The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers. FEBS Lett 226: 115-120. PMID: 2446925
13. Simpson LL (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212: 16-21. PMID: 6243359
14. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580: 2011-2014. PMID: 16545378
15. Fischer A, Montal M (2007) Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A 104: 10447-10452. PMID: 17563359
16. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832-835. PMID: 1331807
17. Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, Benfenati F, et al. (1993) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 335: 99-103. PMID: 8243676
18. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365: 160-163. PMID: 8103915
19. Brunger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, Montal M (2007) Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 3: 1191-1194. PMID: 17907800
20. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ (1993) Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: DasGupta BR, editor. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York: Plenum Press. pp. 473-476.
21. Black RE, Gunn RA (1980) Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 69: 567-570. PMID: 7191633
22. Hibbs RG, Weber JT, Corwin A, Allos BM, Abd el Rehim MS, Sharkawy SE, et al. (1996) Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 23: 337-340. PMID: 8842274
23. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354: 462-471. PMID: 16452558
24. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318: 1343-1351. PMID: 16782822
25. Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, et al. (2004) Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods 288: 55-60. PMID: 15183085
26. Takahashi T, Joshi SG, Al-Saleem F, Ancharski D, Singh A, Nasser Z, et al. (2009) Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27: 2616-2624. doi: 10.1016/j.vaccine.2009.02.051 PMID: 19428868
27. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, et al. (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444: 1096-1100. PMID: 17167418
28. Jin R, Rummel A, Binz T, Brunger AT (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444: 1092-1095. PMID: 17167421
29. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 4: e1000129. doi: 10.1371/journal.ppat.1000129 PMID: 18704164
30. Ho M, Chang LH, Pires-Alves M, Thyagarajan B, Bloom JE, Gu Z, et al. (2011) Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel 24: 247-253. doi: 10.1093/protein/gzq093 PMID: 21051321
31. Dickerson TJ, Janda KD (2006) The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol 1: 359-369. PMID: 17163773
32. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, et al. (2009) Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A 106: 1330-1335. doi: 10.1073/pnas.0812839106 PMID: 19164566
33. Wilson BA, Ho M (2014) Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem 14: 2081-2093. PMID: 25335885
34. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, et al. (2007) Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 282: 5004-5014. PMID: 17092934
35. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, Schmidt JJ, et al. (2006) Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem 14: 395-408. PMID: 16203152
36. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432: 925-929. PMID: 15592454
37. Muller J, Isermann B, Ducker C, Salehi M, Meyer M, Friedrich M, et al. (2009) An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 16: 442-451. doi: 10.1016/j.chembiol.2009.03.007 PMID: 19389630
38. Wu Y, Eigenbrot C, Liang WC, Stawicki S, Shia S, Fan B, et al. (2007) Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc Natl Acad Sci U S A 104: 19784-19789. PMID: 18077410
39. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, et al. (2010) A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alphaexosite binding region. J Mol Biol 397: 1106-1118. doi: 10.1016/j.jmb.2010.01.070 PMID: 20138889
40. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, et al. (2005) Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 351: 158-169. PMID: 16002090
41. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-597. PMID: 1748994
42. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, et al. (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25: 107-116. PMID: 17173035
43. Pires-Alves M, Ho M, Aberle KK, Janda KD, Wilson BA (2009) Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon 53: 392-399. doi: 10. 1016/j.toxicon.2008.12.016 PMID: 19168088
44. Ho M, Goh CH, Brothers MC, Wang S, Young RL, Ou Y, et al. (2012) Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. Protein Science 21: 318-326. doi: 10.1002/pro.2017 PMID: 22170566
45. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD (2007) Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol 365: 196-210. PMID: 17059824
46. Cunningham BC, Wells JA (1989) High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244: 1081-1085. PMID: 2471267
47. Krieglstein KG, DasGupta BR, Henschen AH (1994) Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J Protein Chem 13: 49-57. PMID: 8011071
48. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, et al. (1998) Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A 95: 6157-6162. PMID: 9600934
49. Segelke B, Knapp M, Kadkhodayan S, Balhorn R, Rupp B (2004) Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc Natl Acad Sci U S A 101: 6888-6893. PMID: 15107500
50. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ, et al. (2008) Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 3: e3023. doi: 10.1371/journal.pone.0003023 PMID: 18714390
51. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, et al. (2014) Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs 6: 446-459. doi: 10.4161/mabs.27773 PMID: 24492304
52. Hu X, Legler PM, Southall N, Maloney DJ, Simeonov A, Jadhav A (2014) Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening. J Comput Aided Mol Des 28: 765-778. doi: 10.1007/s10822-014-9758-7 PMID: 24958623
53. Farrow B, Wong M, Malette J, Lai B, Deyle KM, Das S, et al. (2015) Epitope Targeting of Tertiary Protein Structure Enables Target-Guided Synthesis of a Potent In-Cell Inhibitor of Botulinum Neurotoxin. Angew Chem Int Ed Engl.
54. Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, et al. (2012) Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J 279: 2555-2567. doi: 10.1111/j.1742-4658.2012.08638.x PMID: 22607388
55. Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, et al. (2006) Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther 13: 646-651. PMID: 16341056
56. Jensen MJ, Smith TJ, Ahmed SA, Smith LA (2003) Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41: 691-701. PMID: 12727273
57. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, et al. (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99: 11346-11350. PMID: 12177434
58. Bradbury A. M MJD (2004) Phage antibody libraires; Tim Clackson HBL, editor: Oxford University Press.
59. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, et al. (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nature biotechnology 25: 107-116. PMID: 17173035